The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Open accessAbstract
Recent morphologic, immunohistochemical and molecular genetic studies have led to the development of a new paradigm for the pathogenesis and origin of epithelial ovarian cancer (EOC) based on a dualistic model of carcinogenesis that divides EOC into two broad categories designated type I and type II. Type I tumors are comprised of low-grade serous, low-grade endometrioid, clear cell and mucinous carcinomas and Brenner tumors. They are generally indolent, present in stage I (tumor confined to the ovary) and are characterized by specific mutations, including KRAS, BRAF, ERBB2, CTNNB1, PTEN PIK3CA, ARID1A, and PPPR1A, which target specific cell signaling pathways. Type I tumors rarely harbor TP53 and are relatively stable genetically. Type II tumors are comprised of high-grade serous, high-grade endometrioid, malignant mixed mesodermal tumors (carcinosarcomas) and undifferentiated carcinomas. They are aggressive, present in advanced stage, and have a very high frequency of TP53 mutations but rarely harbor the mutations detected in type I tumors. In addition, type II tumors have molecular alterations that perturb expression of BRCA either by mutation of the gene or by promotor methylation. A hallmark of these tumors is that they are genetically highly unstable. Recent studies strongly suggest that fallopian tube epithelium (benign or malignant) that implants on the ovary is the source of low-grade and high-grade serous carcinoma rather than the ovarian surface epithelium as previously believed. Similarly, it is widely accepted that endometriosis is the precursor of endometrioid and clear cell carcinomas and as endometriosis is thought to develop from retrograde menstruation these tumors can also be regarded as involving the ovary secondarily. The origin of mucinous and transitional cell (Brenner) tumors is still not well established, although recent data suggest a possible origin from transitional epithelial nests located in paraovarian locations at the tubo-peritoneal junction. Thus, it now appears that type I and type II ovarian tumors develop independently along different molecular pathways, and that both types develop outside the ovary and involve it secondarily. If this concept is confirmed it leads to the conclusion that the only true primary ovarian neoplasms are gonadal stromal and germ cell tumors analogous to testicular tumors. This new paradigm of ovarian carcinogenesis has important clinical implications. By shifting the early events of ovarian carcinogenesis to the fallopian tube and endometrium instead of the ovary, prevention approaches, for example, salpingectomy with ovarian conservation, may play an important role in reducing the burden of ovarian cancer while preserving hormonal function and fertility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structure of Scientific Revolutions: 50th Anniversary Edition
Kuhn, T. S., & Hacking, I. (2012) · doi:10.7208/chicago/9780226458144.001.0001 · Cited by 21,170
The Structure of Scientific Revolutions
Kuhn, T. S. (1996) · doi:10.7208/chicago/9780226458106.001.0001 · Cited by 7,281
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Firminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,042
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
Self-citationBulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Cited by
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
CA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., & Di, W. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-19 · Cited by 528
Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., Setiawan, V. W., Visvanathan, K., Weiderpass, E., Adami, H.-O., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.8178 · Cited by 514
“This is important etiologically and further supports the differentiation of these two groups of serous carcinomas as proposed in models based on somatic mutations.(8,9) However, in population-based studies, the grade reported on pathology reports may not be reliable, and low-grade serous carcinomas account for only ap…”
BackgroundCollaborative Group on Epidemiological Studies of Ovarian Cancer (2015) · The Lancet · doi:10.1016/s0140-6736(14)61687-1 · Cited by 472
Coburn, S. B., Bray, F., Sherman, M. E., & Trabert, B. (2017) · International Journal of Cancer · doi:10.1002/ijc.30676 · Cited by 453
Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study
Falconer, H., Yin, L., Gronberg, H., & Altman, D. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju410 · Cited by 436
Spiliotis, J., Halkia, E., Lianos, E., Kalantzi, N., Grivas, A., Efstathiou, E., & Giassas, S. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4157-9 · Cited by 434
Webb, J. R., Milne, K., Watson, P., deLeeuw, R. J., & Nelson, B. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1877 · Cited by 434
Ovarian Cancer: A Heterogeneous Disease
Kossaï, M., Leary, A., Scoazec, J.-Y., & Genestie, C. (2018) · Pathobiology · doi:10.1159/000479006 · Cited by 388
Kuhn, E., Kurman, R. J., Vang, R., Sehdev, A. S., Han, G., Soslow, R., Wang, T., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3023 · Cited by 387
Self-citationBanerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Henderson, J. T., Webber, E. M., & Sawaya, G. F. (2018) · JAMA · doi:10.1001/jama.2017.21421 · Cited by 348
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
Kurman, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt463 · Cited by 336
Self-citationOvarian cancer progression is controlled by phenotypic changes in dendritic cells
Scarlett, U. K., Rutkowski, M. R., Rauwerdink, A. M., Fields, J., Escovar-Fadul, X., Baird, J., Cubillos-Ruiz, J. R., Jacobs, A. C., Gonzalez, J. L., Weaver, J., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111413 · Cited by 315
The disparate origins of ovarian cancers: pathogenesis and prevention strategies
Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L., & Huntsman, D. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.113 · Cited by 300
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
Daly, M. B., Pilarski, R., Axilbund, J. E., Berry, M., Buys, S. S., Crawford, B., Farmer, M., Friedman, S., Garber, J. E., Khan, S., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0018 · Cited by 292
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
McConechy, M. K., Ding, J., Senz, J., Yang, W., Melnyk, N., Tone, A. A., Prentice, L. M., Wiegand, K. C., McAlpine, J. N., Shah, S. P., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.107 · Cited by 288
McAlpine, J. N., Hanley, G. E., Woo, M. M. M., Tone, A. A., Rozenberg, N., Swenerton, K. D., Gilks, C. B., Finlayson, S. J., Huntsman, D. G., & Miller, D. M. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.01.003 · Cited by 286
Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms
Vang, R., Shih, I., & Kurman, R. J. (2013) · Histopathology · doi:10.1111/his.12046 · Cited by 281
Self-citationGenomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Wang, Y. K., Bashashati, A., Anglesio, M. S., Cochrane, D. R., Grewal, D. S., Ha, G., McPherson, A., Horlings, H. M., Senz, J., Prentice, L. M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3849 · Cited by 273
Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S., & Sehouli, J. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4035-8 · Cited by 261
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Rojas, V., Hirshfield, K., Ganesan, S., & Rodriguez-Rodriguez, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122113 · Cited by 254
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 253
Matsuzaki, S., & Darcha, C. (2012) · Human Reproduction · doi:10.1093/humrep/der442 · Cited by 216
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
“There is a potential that molecular targeting therapy could prolong disease-free interval and improve overall survival in patients with advanced stage low grade serous carcinomas when combined with conventional therapeutic modalities.(49)”
BackgroundEvidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73
The Link Between Endometriosis and Ovarian Cancer
Nezhat, F. R., Pejovic, T., Reis, F. M., & Guo, S.-W. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000100 · Cited by 58
The Endometriotic Tumor Microenvironment in Ovarian Cancer
Wendel, J. R. H., Wang, X., & Hawkins, S. M. (2018) · Cancers · doi:10.3390/cancers10080261 · Cited by 51
Epigenetic aberration of gene expression in endometriosis
Izawa, M. (2013) · Frontiers in Bioscience · doi:10.2741/e669 · Cited by 49
Liao, T.-L., Lee, Y.-C., Tzeng, C.-R., Wang, Y.-P., Chang, H.-Y., Lin, Y.-F., & Kao, S.-H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.022 · Cited by 44
Li, Q., Sun, Y., Zhang, X., Wang, L., Wu, W., Wu, M., Meng, C., & Liu, G. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1595278 · Cited by 30
Transformation of Abdominal Wall Endometriosis to Clear Cell Carcinoma
Ruiz, M. P., Wallace, D. L., & Connell, M. T. (2015) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2015/123740 · Cited by 19
“Endometriosis has been proposed as a precursor of clear cell carcinoma of the ovary [4].”
BackgroundA comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
Němejcová, K., Bártů, M. K., Michálková, R., Drozenová, J., Fabian, P., Fadare, O., Hausnerová, J., Laco, J., Matěj, R., Méhes, G., et al. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01300-4 · Cited by 4
“Background The current WHO classification distinguishes between five major histological types of ovarian carcinomas with distinct histological features, immunophenotype, molecular abnormalities, precursors, risk factors, and responsiveness to therapy: high grade serous carcinoma (HGSC), low grade serous carcinoma (LGS…”
Background
Metadata
- Authors
- Kurman, R. J., & Shih, I.-M.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 42
- Issue
- 7
- Pages
- 918-931
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W1974756790
- Cited by
- 1,073
- References
- 89
- FWCI
- 103.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.